Last reviewed · How we verify
NCT04704843
A Study of Guselkumab in Adult Participants With Celiac Disease
Phase 1 trial testing Guselkumab in Celiac Disease. Withdrawn.
13 September 2021
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Start date | 17 June 2021 |
| Primary completion | 13 September 2021 |
| Estimated completion | 13 September 2021 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Guselkumab (GUSELKUMAB) — full drug profile →
- Placebo
Conditions studied
- Celiac Disease — all drugs for Celiac Disease →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
Adults 18 to 75, any sex, with Celiac Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From an understanding of etiopathogenesis to novel therapies-what is new in the treatment of celiac disease?
Skoracka K, Hryhorowicz S, Tovoli F, Raiteri A, et al · · 2024 · cited 2× · PMID 38698821 · DOI 10.3389/fphar.2024.1378172
Verify or expand the search:
- PubMed search for NCT04704843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Guselkumab
Trials testing the same drug.
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06916390 — GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis · Phase 4 · not yet recruiting
- NCT07141004 — A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) · Phase 4 · recruiting
Other recruiting trials for Celiac Disease
Currently open trials in the same condition.
- NCT07239336 — Study of DONQ52 in Active Celiac Disease · Phase 2 · recruiting
- NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease · NA · recruiting
- NCT07063823 — A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease · Phase 1 · recruiting
- NCT06982963 — Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease · Phase 2 · recruiting
- NCT07177287 — The Effect of a Navigator Nurse- Supported Mobile Application Developed Based on the IMB Model on the Quality of Life of · NA · recruiting
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04704843 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04704843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing